Used as main image by Phynd in search results and profile page

Nan Sethakorn, MD

Medical Oncology, Hematology & Oncology, Internal Medicine

Provider Groups

  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact

(888)584-7888
Provider Groups
  • Loyola Medicine Physician

  • Loyola Physician Partners

Primary Contact
(888)584-7888

Services & Specialties

Areas of Specialization

  • Hematology & Oncology
  • Internal Medicine
  • Medical Oncology

Clinical Interests

Conditions Treated

  • lung cancer
  • cancer chemotherapy
  • targeted molecular therapy
  • cancer immunotherapy

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood , IL 60153

Loyola University Medical Center

About

I am a physician-scientists focusing on the treatment of patients with lung cancer, and in the laboratory I study how the tumor microenvironment (TME) in bone metastases affect treatment responses of lung cancer using tumor organoids and non-cancerous cells donated from patients. The goal of our research is to find new ways to overcome treatment resistance and new ways to treat bone metastases, both of which are major concerns in the treatment of lunch cancer.

Academic Title

Assistant Professor

Additional Resources

Education & Certifications

Education

Education:
University of Chicago,Pritzker School of Medicine (2015)

Education:
University of Chicago Division of Biological Sciences Pritzker School of Medicine (2015)

Residency:
University of Wisconsin Hospitals and Clinics (Madison) (2017)

Fellowship:
University of Wisconsin Hospitals and Clinics (Madison) (2021)

Fellowship:
University of Wisconsin Hospitals and Clinics (Madison) (2021)

Board Certifications

Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (2021)

Internal Medicine, Internal Medicine, American Board of (2018)

Provider Groups

Loyola Medicine Physician

Loyola Physician Partners

Publications

  • Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. Bassetti, M. F.; Morris, B. A.; Sethakorn, N.; Lang, J. M.; Schehr, J. L.; Zhao, S. G.; Morris, Z. S.; Buehler, D.; Eickhoff, J. C.; Harari, P. M.; Traynor, A. M.; Campbell, T. C.; Baschnagel, A. M.; Leal, T. A.; International journal of radiation oncology, biology, physics